TransCon hGH + daily hGH
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency
Conditions
Growth Hormone Deficiency, Endocrine System Diseases, Hormones, Pituitary Diseases, Pituitary Disease, Anterior
Trial Timeline
Dec 30, 2019 → Apr 1, 2022
NCT ID
NCT04326374About TransCon hGH + daily hGH
TransCon hGH + daily hGH is a phase 3 stage product being developed by Ascendis Pharma for Growth Hormone Deficiency. The current trial status is unknown. This product is registered under clinical trial identifier NCT04326374. Target conditions include Growth Hormone Deficiency, Endocrine System Diseases, Hormones.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04326374 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Growth Hormone Deficiency